NASDAQ:ANIP ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis $76.14 +0.75 (+0.99%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$76.10 -0.04 (-0.05%) As of 09/18/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About ANI Pharmaceuticals Stock (NASDAQ:ANIP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ANI Pharmaceuticals alerts:Sign Up Key Stats Today's Range$74.21▼$77.4150-Day Range$70.19▼$82.6352-Week Range$69.58▼$98.04Volume1.16 million shsAverage Volume368,306 shsMarket Capitalization$1.75 billionP/E Ratio16.41Dividend YieldN/APrice Target$103.00Consensus RatingModerate Buy Company Overview ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas. ANI’s portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines. Its products span areas such as endocrinology, ophthalmology, central nervous system disorders, oncology and other specialty and primary-care markets. Headquartered in Baudette, Minnesota, ANI operates primarily in the United States and has expanded its product portfolio through internal development, acquisitions and licensing arrangements. The company acquired Novitium Pharma in 2020, adding additional generic products and development capabilities. ANI is led by Nikhil Lalwani, who serves as president and chief executive officer.AI Generated. May Contain Errors. Read More ANI Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks84th Percentile Overall ScoreANIP MarketRank™: ANI Pharmaceuticals scored higher than 84% of companies evaluated by MarketBeat, and ranked 103rd out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingANI Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 4 hold ratings, and no sell ratings.Upside PotentialANI Pharmaceuticals has a consensus price target of $103.00, representing about 35.3% upside from its current price of $76.14.Amount of Analyst CoverageANI Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about ANI Pharmaceuticals' stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth9.83% Earnings GrowthEarnings for ANI Pharmaceuticals are expected to grow by 9.83% in the coming year, from $7.83 to $8.60 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ANI Pharmaceuticals is 16.41, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.90.Price to Earnings Ratio vs. SectorThe P/E ratio of ANI Pharmaceuticals is 16.41, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 273.81.Price to Book Value per Share RatioANI Pharmaceuticals has a P/B Ratio of 3.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about ANI Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.94% of the float of ANI Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverANI Pharmaceuticals has a short interest ratio ("days to cover") of 9.22.Change versus previous monthShort interest in ANI Pharmaceuticals has recently decreased by 1.63%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldANI Pharmaceuticals does not currently pay a dividend.Dividend GrowthANI Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News Sentiment0.76 News SentimentANI Pharmaceuticals has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 15 news articles for ANI Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 4 people have searched for ANIP on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added ANI Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, ANI Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,177,695.00 in company stock.Percentage Held by Insiders8.10% of the stock of ANI Pharmaceuticals is held by insiders.Percentage Held by Institutions76.05% of the stock of ANI Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ANI Pharmaceuticals' insider trading history. Receive ANIP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ANI Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANIP Stock News HeadlinesNikhil Lalwani Sells 5,400 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) StockSeptember 18 at 6:15 AM | americanbankingnews.comANI Pharmaceuticals (NASDAQ:ANIP) CEO Sells 5,400 SharesSeptember 17 at 6:52 AM | insidertrades.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 19 at 1:00 AM | Profits Run (Ad)Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) StockSeptember 15, 2026 | insidertrades.comANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 14, 2026 | seekingalpha.comANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Given Average Recommendation of "Moderate Buy" by AnalystsSeptember 13, 2026 | americanbankingnews.comStephen Carey Sells 2,850 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) StockSeptember 2, 2026 | insidertrades.comANI Pharmaceuticals (NASDAQ:ANIP) CEO Nikhil Lalwani Sells 5,400 SharesAugust 27, 2026 | insidertrades.comSee More Headlines ANIP Stock Analysis - Frequently Asked Questions How have ANIP shares performed this year? ANI Pharmaceuticals' stock was trading at $78.94 at the beginning of 2026. Since then, ANIP stock has decreased by 3.5% and is now trading at $76.14. How were ANI Pharmaceuticals' earnings last quarter? ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) issued its quarterly earnings data on Friday, August, 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating the consensus estimate of $2.04 by $0.17. The firm's quarterly revenue was up 25.8% on a year-over-year basis. Read the conference call transcript. Who are ANI Pharmaceuticals' major shareholders? ANI Pharmaceuticals' top institutional investors include Ranger Investment Management L.P. (1.51%), Deutsche Bank AG (1.42%), William Blair Investment Management LLC (1.13%) and Penn Capital Management Company LLC (0.90%). Insiders that own company stock include Muthusamy Shanmugam, Nikhil Lalwani, Stephen P Carey, Chad Gassert, James G Marken, Christopher Mutz, Ori Gutwerg, Meredith Cook, Krista Davis, Thomas Haughey, Patrick D Walsh, Thomas Andrew Rowland, Jeanne Thoma, Renee P Tannenbaum, Antonio R Pera and Matthew J Leonard. View institutional ownership trends. How do I buy shares of ANI Pharmaceuticals? Shares of ANIP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of ANI Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that ANI Pharmaceuticals investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings8/07/2026Today9/19/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ANIP's financial health is in the Red zone, according to TradeSmith. ANIP has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ANIP Previous SymbolNASDAQ:BPAX CIK1023024 Webwww.anipharmaceuticals.com Phone(218) 634-3500Fax218-634-3540Employees970Year Founded1996Price Target and Rating Average Price Target for ANI Pharmaceuticals$103.00 High Price Target$119.00 Low Price Target$90.00 Potential Upside/Downside+35.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)$4.64 Trailing P/E Ratio16.41 Forward P/E Ratio9.72 P/E GrowthN/ANet Income$78.34 million Net Margins11.07% Pretax Margin14.57% Return on Equity27.37% Return on Assets10.47% Debt Debt-to-Equity Ratio0.99 Current Ratio2.91 Quick Ratio2.41 Sales & Book Value Annual Sales$883.37 million Price / Sales1.98 Cash Flow$10.03 per share Price / Cash Flow7.59 Book Value$24.03 per share Price / Book3.17Miscellaneous Outstanding Shares22,970,000Free Float21,109,000Market Cap$1.75 billion OptionableOptionable Beta0.45 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:ANIP) was last updated on 9/19/2026 by MarketBeat.com Staff. From Our PartnersThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredMILLIONAIRE MASTERCLASS INVITE: AltucherJames Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...Paradigm Press | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ANI Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ANI Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
